Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achieve Life Sciences (ACHV) and Intercept Pharma (ICPT).
Achieve Life Sciences (ACHV)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences, with a price target of $10.00. The company’s shares closed last Monday at $0.40, close to its 52-week low of $0.23.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of 0.7% and a 33.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Currently, the analyst consensus on Achieve Life Sciences is a Moderate Buy with an average price target of $6.00.
See today’s analyst top recommended stocks >>
Intercept Pharma (ICPT)
In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Intercept Pharma, with a price target of $48.00. The company’s shares closed last Monday at $46.77.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 17.3% and a 44.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $134.29, implying a 184.2% upside from current levels. In a report released today, Stifel Nicolaus also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
